Media headlines about Kura Oncology (NASDAQ:KURA) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kura Oncology earned a news impact score of 0.11 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.0752322408828 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Kura Oncology (NASDAQ:KURA) opened at 10.35 on Tuesday. The company’s 50-day moving average price is $8.81 and its 200 day moving average price is $8.52. Kura Oncology has a 1-year low of $3.89 and a 1-year high of $12.10. The firm’s market capitalization is $203.55 million.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Monday, May 15th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.05. On average, equities analysts anticipate that Kura Oncology will post ($1.63) EPS for the current year.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 12th. Oppenheimer Holdings, Inc. set a $16.00 price objective on Kura Oncology and gave the company a “buy” rating in a research note on Wednesday, June 14th. Finally, Cann reissued a “buy” rating and set a $16.00 target price on shares of Kura Oncology in a research note on Monday, May 15th.

WARNING: “Kura Oncology (NASDAQ:KURA) Earns News Sentiment Rating of 0.11” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with's FREE daily email newsletter.